Share-based Payment Arrangement, Expense of Atea Pharmaceuticals, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Atea Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Atea Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,517,000, a 63% decline year-over-year.
  • Atea Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $30,432,000, a 39% decline year-over-year.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $51,767,000, a 4.7% increase from 2023.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $49,428,000, a 5.8% increase from 2022.
  • Atea Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $46,718,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Atea Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $30,432,000 $4,517,000 -$7,647,000 -63% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $38,079,000 $4,667,000 -$8,053,000 -63% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $46,132,000 $6,951,000 -$5,635,000 -45% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $51,767,000 $14,297,000 +$2,140,000 +18% 01 Oct 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
Q3 2024 $49,627,000 $12,164,000 -$219,000 -1.8% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $49,846,000 $12,720,000 +$367,000 +3% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $49,479,000 $12,586,000 +$51,000 +0.41% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $49,428,000 $12,157,000 +$512,000 +4.4% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
Q3 2023 $48,916,000 $12,383,000 +$879,000 +7.6% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $48,037,000 $12,353,000 +$445,000 +3.7% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $47,592,000 $12,535,000 +$874,000 +7.5% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $46,718,000 $11,645,000 +$294,000 +2.6% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $46,424,000 $11,504,000 +$514,000 +4.7% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $45,910,000 $11,908,000 +$1,901,000 +19% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $44,009,000 $11,661,000 +$4,388,000 +60% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $39,621,000 $11,351,000 +$8,530,000 +302% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $31,091,000 $10,990,000 +$6,752,000 +159% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $24,339,000 $10,007,000 +$9,798,000 +4688% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $14,541,000 $7,273,000 +$7,084,000 +3748% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $7,457,000 $2,821,000 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $4,238,000 +$4,081,000 +2599% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $209,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $189,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q3 2019 $157,000 01 Jul 2019 30 Sep 2019 10-Q 10 Dec 2020 2020 Q3

Atea Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $51,767,000 +$2,339,000 +4.7% 01 Jan 2024 31 Dec 2024 10-K 06 Mar 2025 2024 FY
2023 $49,428,000 +$2,710,000 +5.8% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2025 2024 FY
2022 $46,718,000 +$7,097,000 +18% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $39,621,000 +$32,164,000 +431% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 $7,457,000 +$6,833,000 +1095% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $624,000 +$210,000 +51% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $414,000 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.